传统身心运动疗法对慢性心肺呼吸困难的影响:系统综述与荟萃分析
结果显示TMBM在6分钟步行距离和生活质量上具有正向效果,效果与EBCR相似甚至更优,或可作为EBCR的补充或替代策略。
要点
- TMBM在COPD和心衰患者的6MWD上均显著优于EBCR。
- TMBM在心衰患者生活质量上显著优于EBCR,COPD仅呈非显著趋势。
- TMBM联合EBCR较单用EBCR在COPD生活质量和6MWD上显著改善。
核心结论
- TMBM对患者6MWD和生活质量有正向效果,效果与EBCR相似甚至更优。
- TMBM或可作为EBCR的补充或替代策略用于治疗计划。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、Scopus、Web of Science和中国知网至2021年7月2日。
- 纳入比较TMBM vs EBCR及TMBM+EBCR vs TMBM治疗慢性心肺呼吸困难的研究。
主要发现
- TMBM vs 单用EBCR:COPD患者6MWD的MD=12.22 m(95%CI 5.94–18.50;I2=56%),心衰患者MD=43.65 m(95%CI 7.91–79.38;I2=0%),均显著 favour TMBM。
- TMBM vs 单用EBCR:心衰患者生活质量MD=-9.19(95%CI -11.05至-7.32;I2=0%),显著 favour TMBM;COPD患者SMD=-0.31(95%CI -0.62至0.01;I2=78%),为非显著趋势。
- TMBM+EBCR vs 单用EBCR:COPD患者生活质量SMD=-0.52(95%CI -0.94至-0.10;I2=86%),心衰患者MD=-2.82(95%CI -4.99至-0.64;I2=0%),均显著改善。
- TMBM+EBCR vs 单用EBCR:COPD患者6MWD的MD=16.76 m(95%CI 10.24–23.29;I2=0%),显著 favour 联合组;心衰患者MD=13.77 m(95%CI -1.01至28.54;I2=65%),仅为轻微趋势。
临床怎么用
- 可考虑将TMBM作为EBCR的补充或替代方案,用于慢性心肺呼吸困难患者。
- 对COPD患者,TMBM联合EBCR可进一步改善生活质量和6MWD。
- 对心衰患者,TMBM在6MWD和生活质量上均显示出优于EBCR的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate whether traditional mind-body movement therapy (TMBM) can be used as a complementary or alternative therapy for exercise-based cardiopulmonary rehabilitation (EBCR) on chronic cardiopulmonary dyspnoea. METHODS: PubMed, Embase, Scopus, Web of Science and China National Knowledge Infrastructure were searched from their inception to 2 July 2021. Randomised clinical trials evaluating the effectiveness of TMBM versus EBCR, and TMBM +EBCR versus TMBM in the treatment of chronic cardiopulmonary dyspnoea were selected. The outcomes were exercise capacity (6 min walk distance, 6MWD) and quality of life (QoL). RESULTS: Thirty-four randomised clinical trials with 2456 patients were included. For TMBM vs EBCR alone, statistically significant improvements in the 6MWD favoured the TMBM for chronic obstructive pulmonary disease (COPD) (mean difference(MD)=12.22 m; 95% CI 5.94 to 18.50; I2=56%) and heart failure (HF) patients (MD=43.65 m; 95% CI 7.91 to 79.38; I2=0%). Statistically significant improvements in QoL also favoured TMBM over EBCR for patients with HF(MD=-9.19; 95% CI -11.05 to -7.32; I2=0%) but non-significant trend for COPD (standardised mean difference (SMD)=-0.31; 95% CI -0.62 to 0.01; I2=78%). Comparisons of TMBM +EBCR versus EBCR alone revealed significant improvements in the QoL for COPD (SMD=-0.52; 95% CI -0.94 to -0.10; I2=86%) and patients with HF (MD=-2.82; 95% CI -4.99 to -0.64; I2=0%). The 6MWD results favoured the TMBM +EBCR for patients with COPD (MD=16.76 m; 95% CI 10.24 to 23.29; I2=0%), but only showed a slight trend towards additional benefits of TMBM +EBCR in the HF studies (MD=13.77 m; 95% CI -1.01 to 28.54; I2=65%) . CONCLUSIONS: TMBM has positive effects on patients' 6MWD and QoL, with similar or even better effects than EBCR. It may be beneficial to use TMBM as a supplementary or alternative strategy for EBCR in treatment plans. PROSPERO REGISTRATION NUMBER: CRD42021241181.
引用
- Zhang T, Zhou R, Wang T, et al. Effects of traditional mind-body movement therapy on chronic cardiopulmonary dyspnoea: a systematic review and meta-analysis. Thorax. 2022. PMID: 35483892. doi:10.1136/thoraxjnl-2021-218030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。